Low-Dose Paclitaxel Prior to Intratumoral Dendritic Cell Vaccine Modulates Intratumoral Cytokine Network and Lung Cancer Growth
- 15 September 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (18), 5455-5462
- https://doi.org/10.1158/1078-0432.ccr-07-0517
Abstract
Purpose: The main goal of this study was to provide the “proof-of-principle” that low-dose paclitaxel is able to change the tumor microenvironment and improve the outcome of intratumoral dendritic cell vaccine in a murine lung cancer model. Experimental Design: We evaluated the antitumor potential and changes in the intratumoral milieu of a combination of low-dose chemotherapy and dendritic cell vaccine in the Lewis lung carcinoma model in vivo. Results: The low-dose paclitaxel, which induced apoptosis in ∼10% of tumor cells, was not toxic to bone marrow cells and dendritic cells and stimulated dendritic cell maturation and function in vitro. Although tumor cells inhibited dendritic cell differentiation in vitro, this immunosuppressive effect was abrogated by the pretreatment of tumor cells with low-dose paclitaxel. Based on these data, we next tested whether pretreatment of tumor-bearing mice with low-dose paclitaxel in vivo would improve the antitumor potential of dendritic cell vaccine administered intratumorally. Significant inhibition of tumor growth in mice treated with low-dose paclitaxel plus intratumoral dendritic cell vaccine, associated with increased tumor infiltration by CD4+ and CD8+ T cells and elevated tumor-specific IFN-γ production by draining lymph node cells, was revealed. Using a novel intratumoral microdialysis technique and Luminex technology for collecting and characterizing soluble factors released within the tumor bed for several days in live freely moving animals, we showed that low-dose paclitaxel altered the cytokine network at the tumor site. Conclusions: Our data indicate that low-dose chemotherapy before intratumoral delivery of dendritic cells might be associated with beneficial alterations of the intratumoral microenvironment and thus support antitumor immunity.Keywords
This publication has 48 references indexed in Scilit:
- Combination of Low-Dose Gemcitabine and Recombinant Quail Vascular Endothelial Growth Factor Receptor-2 as a Vaccine Induces Synergistic Antitumor ActivitiesOncology, 2005
- Taxanes for advanced non-small cell lung cancerExpert Opinion on Pharmacotherapy, 2002
- Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo.2001
- Current Standards of Care in Small-Cell and Non-Small-Cell Lung CancerOncology, 2001
- Low-Level Monocyte Chemoattractant Protein-1 Stimulation of Monocytes Leads to Tumor Formation in Nontumorigenic Melanoma CellsThe Journal of Immunology, 2001
- IL (interleukin)-1alpha promotes nuclear factor-kappaB and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinomas.2001
- Interleukin-13 and interleukin-13 receptor in Hodgkin's disease: possible autocrine mechanism and involvement in fibrosisHistopathology, 2001
- Selective cancer cell killing by α-tocopheryl succinateBritish Journal of Cancer, 2001
- Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancerCancer, 2000
- Vitamin E Succinate Induces Apoptosis in Human Prostate Cancer Cells: Role for Fas in Vitamin E Succinate-Triggered ApoptosisNutrition and Cancer, 2000